Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development stage company, is focused on safer, more effective, less invasive and more economical oncology and dermatology therapies. Currently, the company is conducting Phase 2 clinical trials of their proprietary drugs designed to treat psoriasis, metastatic melanoma, and atopic dermatitis. Provectus has developed multiple intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For further information, visit the Company’s web site at www.pvct.com.
- 18 years ago
QualityStocks
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Greenland Mines Ltd (NASDAQ: GRML) Raises More Than $42 Million, Completes Sarfartoq Field Program
Greenland Mines (NASDAQ: GRML) raised more than $42 million from existing investors through a registered…
-
QualityStocksNewsBreaks – Beeline Holdings, Inc. (NASDAQ: BLNE) Bizumentary to Premiere Sept. 24 Across National Networks
Beeline Holdings (NASDAQ: BLNE) announced that its “Bizumentary,” produced in partnership with Emmy Award-winning Loft…
-
QualityStocksNewsBreaks – Nocera, Inc. (NASDAQ: NCRA) Enters Worldwide Joint Distribution Agreement With E-PRO
Nocera (NASDAQ: NCRA) entered into a Strategic Partnership and Joint Distribution Agreement with Taiwan-based E-PRO…